Deep Brain Stimulation Probes New Frontiers
Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.
You may also be interested in...
The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.
The field of neuromodulation has produced numerous start-ups and a decent amount of fundraising activity over the past six years, but exits are scarce.
The two firms are building on a 2009 agreement to offer an MRI-guided alternative for cardiac catheter ablation procedures.